In our study, the rate of grade 3-5 adverse reactions and pneumonitis in patients receiving CRT/RT and PD-1 inhibitors was 46.3% (95% CI: 32.0%-60.9%, I2: 71%) and 0.8% (95% CI: 0.1%-1.5%, I2: 0%). This evidence concerns the gene PDCD1 and pneumonitis.